{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T21:18:10Z","timestamp":1717795090834},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T00:00:00Z","timestamp":1480032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T00:00:00Z","timestamp":1480032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Epidermal growth factor receptor (EGFR) is usually expressed in squamous cell anal carcinoma (SCAC) and anti-EGFR agents could represent a valid treatment strategy, also considering that <jats:italic>KRAS<\/jats:italic> and <jats:italic>BRAF<\/jats:italic> mutations are rare events in this type of cancer. However, no data are available on <jats:italic>NRAS<\/jats:italic> status in SCAC. In this study we analyzed <jats:italic>NRAS<\/jats:italic> status (exons 2\u20134) by Pyrosequencing in a case series of 50 SCAC patients previously characterized in our laboratory for <jats:italic>KRAS, BRAF, PIK3CA<\/jats:italic> mutations and HPV and HIV infections. We found no mutation in <jats:italic>NRAS<\/jats:italic> gene. These results confirm that since the principal anti-EGFR resistance mechanisms are almost absent in SCAC, anti-EGFR agents should be considered for the treatment of this type of cancer.<\/jats:p>","DOI":"10.1038\/srep37621","type":"journal-article","created":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T10:15:45Z","timestamp":1480068945000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC)"],"prefix":"10.1038","volume":"6","author":[{"given":"Laura","family":"Capelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Casadei Gardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Scarpi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni Luca","family":"Frassineti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Saragoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Puccetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Scartozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Tamberi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jody","family":"Corbelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Ulivi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,25]]},"reference":[{"key":"BFsrep37621_CR1","first-page":"1","volume":"22","author":"M Skamperle","year":"2013","unstructured":"Skamperle, M., Kocjan, B. J., Maver, P. J., Seme, K. & Poljak, M. Human papillomavirus (HPV) prevalence and HPV type distribution in cervical, vulvar, and anal cancers in central and eastern Europe. Acta Dermatovenerol. Alp. Pannonica Adriat. 22, 1\u20135 (2013).","journal-title":"Acta Dermatovenerol. Alp. Pannonica Adriat"},{"key":"BFsrep37621_CR2","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1245\/s10434-007-9491-8","volume":"14","author":"DE Schiller","year":"2007","unstructured":"Schiller, D. E. et al. Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann. Surg. Oncol. 14, 2780\u20132789 (2007).","journal-title":"Ann. Surg. Oncol."},{"key":"BFsrep37621_CR3","first-page":"861","volume":"86","author":"C Faivre","year":"1999","unstructured":"Faivre, C. et al. 5-Fluorouracile and Cisplatinum Combination Chemotherapy for Metastatic Squamous-Cell Anal Cancer. Bull. Cancer 86, 861\u2013865 (1999).","journal-title":"Bull. Cancer"},{"key":"BFsrep37621_CR4","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1038\/bjc.2012.479","volume":"107","author":"A Paliga","year":"2012","unstructured":"Paliga, A. et al. EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors? Br. J. Cancer 107, 1864\u20131868 (2012).","journal-title":"Br. J. Cancer"},{"key":"BFsrep37621_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00280-009-1117-3","volume":"65","author":"MG Zampino","year":"2009","unstructured":"Zampino, M. G., Magni, E., Sonzogni, A. & Renne, G. K-ras status in squamous cell anal carcinoma (SCC): it\u2019s time for target-oriented treatment? Cancer Chemother. Pharmacol. 65, 197\u2013199 (2009).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"BFsrep37621_CR6","doi-asserted-by":"crossref","unstructured":"Van Damme, N. et al. Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer 10, 189-2407-10-189 (2010).","DOI":"10.1186\/1471-2407-10-189"},{"key":"BFsrep37621_CR7","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1159\/000341371","volume":"5","author":"H Barmettler","year":"2012","unstructured":"Barmettler, H., Komminoth, P., Schmid, M. & Duerr, D. Efficacy of Cetuximab in Combination with FOLFIRI in a Patient with KRAS Wild-Type Metastatic Anal Cancer. Case Rep. Oncol. 5, 428\u2013433 (2012).","journal-title":"Case Rep. Oncol"},{"key":"BFsrep37621_CR8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000259615","volume":"77","author":"N Lukan","year":"2009","unstructured":"Lukan, N. et al. Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology 77, 293\u2013299 (2009).","journal-title":"Oncology"},{"key":"BFsrep37621_CR9","first-page":"E82","volume":"6","author":"JE Rogers","year":"2015","unstructured":"Rogers, J. E., Silva, N. N. & Eng, C. Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal. J. Gastrointest. Oncol. 6, E82\u20135 (2015).","journal-title":"J. Gastrointest. Oncol"},{"key":"BFsrep37621_CR10","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1016\/j.ejca.2015.08.029","volume":"51","author":"O Leon","year":"2015","unstructured":"Leon, O., Guren, M. G., Radu, C., Gunnlaugsson, A. & Johnsson, A. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. Eur. J. Cancer 51, 2740\u20132746 (2015).","journal-title":"Eur. J. Cancer"},{"key":"BFsrep37621_CR11","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","volume":"15","author":"V Heinemann","year":"2014","unstructured":"Heinemann, V. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 15, 1065\u20131075 (2014).","journal-title":"Lancet Oncol."},{"key":"BFsrep37621_CR12","doi-asserted-by":"crossref","unstructured":"Ulivi, P. et al. Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study. J. Transl. Med. 10, 87-5876-10-87 (2012).","DOI":"10.1186\/1479-5876-10-87"},{"key":"BFsrep37621_CR13","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","volume":"29","author":"E Van Cutsem","year":"2011","unstructured":"Van Cutsem, E. et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29, 2011\u20132019 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFsrep37621_CR14","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","volume":"11","author":"W De Roock","year":"2010","unstructured":"De Roock, W. et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11, 753\u2013762 (2010).","journal-title":"Lancet Oncol."},{"key":"BFsrep37621_CR15","doi-asserted-by":"publisher","first-page":"e92071","DOI":"10.1371\/journal.pone.0092071","volume":"9","author":"A Casadei Gardini","year":"2014","unstructured":"Casadei Gardini, A. et al. KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC). PLoS One 9, e92071 (2014).","journal-title":"PLoS One"},{"key":"BFsrep37621_CR16","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1016\/j.humpath.2014.08.001","volume":"45","author":"ES Prigge","year":"2014","unstructured":"Prigge, E. S. et al. No evidence of oncogenic KRAS mutations in squamous cell carcinomas of the anogenital tract and head and neck region independent of human papillomavirus and p16(INK4a) status. Hum. Pathol. 45, 2347\u20132354 (2014).","journal-title":"Hum. Pathol."},{"key":"BFsrep37621_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/apm.12306","volume":"123","author":"E Serup-Hansen","year":"2015","unstructured":"Serup-Hansen, E., Linnemann, D., Hogdall, E., Geertsen, P. F. & Havsteen, H. KRAS and BRAF mutations in anal carcinoma. APMIS 123, 53\u201359 (2015).","journal-title":"APMIS"},{"key":"BFsrep37621_CR18","first-page":"513","volume":"29","author":"V Martin","year":"2014","unstructured":"Martin, V. et al. EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer. Histol. Histopathol. 29, 513\u2013521 (2014).","journal-title":"Histol. Histopathol."},{"key":"BFsrep37621_CR19","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/BF02586980","volume":"17","author":"ND Nigro","year":"1974","unstructured":"Nigro, N. D., Vaitkevicius, V. K. & Considine, B. Jr. Combined therapy for cancer of the anal canal: a preliminary report. Dis. Colon Rectum 17, 354\u2013356 (1974).","journal-title":"Dis. Colon Rectum"},{"key":"BFsrep37621_CR20","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1093\/annonc\/mdt368","volume":"24","author":"E Deutsch","year":"2013","unstructured":"Deutsch, E. et al. Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. Ann. Oncol. 24, 2834\u20132838 (2013).","journal-title":"Ann. Oncol."},{"key":"BFsrep37621_CR21","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1002\/cncr.28045","volume":"119","author":"LO Olivatto","year":"2013","unstructured":"Olivatto, L. O. et al. Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. Cancer 119, 2973\u20132980 (2013).","journal-title":"Cancer"},{"key":"BFsrep37621_CR22","first-page":"161","volume":"3","author":"NN Silva","year":"2012","unstructured":"Silva, N. N. & Eng, C. Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapy. J. Adv. Pract. Oncol. 3, 161\u2013169 (2012).","journal-title":"J. Adv. Pract. Oncol"},{"key":"BFsrep37621_CR23","doi-asserted-by":"crossref","unstructured":"Boeckx, C. et al. Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response. BMC Res. Notes 7, 337-0500-7-337 (2014).","DOI":"10.1186\/1756-0500-7-337"},{"key":"BFsrep37621_CR24","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/j.1445-2197.2011.05791.x","volume":"82","author":"P Friedland","year":"2012","unstructured":"Friedland, P. et al. Human papillomavirus and gene mutations in head and neck squamous carcinomas. ANZ J. Surg. 82, 362\u2013366 (2012).","journal-title":"ANZ J. Surg"},{"key":"BFsrep37621_CR25","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1111\/j.1349-7006.2008.00861.x","volume":"99","author":"MA Sheikh Ali","year":"2008","unstructured":"Sheikh Ali, M. A. et al. Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer. Sci. 99, 1589\u20131594 (2008).","journal-title":"Cancer. Sci"},{"key":"BFsrep37621_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","volume":"11","author":"JA Bonner","year":"2010","unstructured":"Bonner, J. A. et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 11, 21\u201328 (2010).","journal-title":"Lancet Oncol."},{"key":"BFsrep37621_CR27","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken, J. B. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359, 1116\u20131127 (2008).","journal-title":"N. Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep37621.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep37621","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep37621.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T03:19:55Z","timestamp":1672888795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep37621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,25]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,23]]}},"alternative-id":["BFsrep37621"],"URL":"https:\/\/doi.org\/10.1038\/srep37621","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,25]]},"assertion":[{"value":"16 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37621"}}